• CRO M&A Market in 2020 (So Far)

    There haven’t been many deals targeting contract research organizations (CRO) in 2020, especially compared to previous years, which makes sense. Life science companies are all slowing down clinical trials (COVID-19 vaccine research excluded) to adhere to social distancing guidelines, meaning CRO services are just not in as high demand. For... Read More »
  • Ophthalmology Groups Are Still Selling

    Despite the effects of COVID-19 on physician groups, investors are still acquiring ophthalmology groups, especially in the third quarter, according to DSO. Just last week, EyeSouth Partners acquired Retina Associates of Middle Georgia (RAMG) for an undisclosed sum. Based in Macon, Georgia, RAMG provides treatment for the retina, macula, and... Read More »
  • Hospice M&A Activity Surges in 2020

    Despite the volatile market conditions for healthcare M&A, hospice targets have remained a remarkably consistent draw for investors, according to data captured in DSO. In the second quarter of 2020, 70% of HH&H transactions were for hospice specific targets, or targets that provided only hospice services, instead of a mix of hospice and... Read More »
  • Teladoc Health and Livongo Health Merge

    The virtual care giant Teladoc Health, Inc. (NYSE: TDOC) is having a wild year. The company’s second-quarter earnings reports showed Teladoc’s year-over-year revenues surged by 85% to $241 million, and its total telehealth visits rose to 2.8 million, a year-over-year increase of 203%, all thanks to the effects of COVD-19. And now,... Read More »
  • Health Care M&A Deals, August 7, 2020

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our Deal Search Online database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week was... Read More »

Q1:17 Biotechnology Deals Keep Climbing

Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, as pharmaceutical companies that have abandoned their own R&D turn to buying up smaller biotechs with promising clinical-stage compounds. The 21st Century Cures Act also benefits this sector, with its billions of dollars in financing for both the “Cancer Moonshot” and the BRAIN Initiative. In the first quarter, 20 of the 62 transactions involved the purchase of an... Read More »